Lucid Psycheceuticals Inc.
Tracked across 6 events · 39 articles · First seen Jun 02, 2026 · Last active Sep 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma and is focused on the research and development of Lucid-MS.
Jun 08, 2026 · 8 articles
Tech
Quantum BioPharma received clearance from the U.S. United States — Food and Drug Administration to launch a phase 2 clinical trial of Lucid-MS, a patented first-in-class drug candidate for multiple sclerosis. Unlike existing MS therapies…
Impact: As Quantum BioPharma's wholly owned subsidiary, Lucid Psycheceuticals conducts the research and development of Lucid-MS, the compound at the center of the cleared trial.
Sep 09, 2026 · 6 articles
Business
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma, mentioned as the developer of Lucid-MS. The stock option grant does not directly affect Lucid, but it is part of the parent company's corporate update.
Aug 21, 2026 · 6 articles
Business
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma Ltd. focused on research and development of Lucid-MS.
Jun 02, 2026 · 6 articles
Business
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma focused on Lucid-MS. It is mentioned in the background but not directly involved in the event.
Jul 07, 2026 · 6 articles
Business
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma focused on Lucid-MS, but not directly involved in the debt settlement.
Jul 20, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Lucid Psycheceuticals Inc. live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard